Cross-Sector entity
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Acadia Pharmaceuticals, the most common co-covered peer. We currently track 1 Cross-Sector story that mention ACP-101, all published on February 27, 2026.
1 verified story tracked
Last mentioned: Feb 27, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Acadia Pharmaceuticals, the most common co-covered peer. We currently track 1 Cross-Sector story that mention ACP-101, all published on February 27, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ACP-101. Shared-story counts are live from our verified record — not editorial picks.
Fiscal Milestone
ACADIA reports record quarterly revenue and achieves annual GAAP profitability.
Trial Setback
Phase 3 ADVANCE-2 trial for pimavanserin in schizophrenia fails to meet primary endpoint.
Commercial Launch
Daybue officially enters the U.S. market with strong initial uptake.
FDA Approval
Daybue (trofinetide) approved as the first treatment for Rett syndrome.
ACADIA Pharmaceuticals reported a transformative fourth quarter, highlighted by the rapid commercial expansion of Daybue for Rett syndrome and the steady performance of Nuplazid. The company has successfully achieved GAAP profitability, signaling a robust shift toward a diversified rare disease and neurology portfolio.
Source: finance.yahoo.com · finance.yahoo.com
